CN1785384A - Chinese medicinal composition for treating tuberculosis and its preparation method - Google Patents
Chinese medicinal composition for treating tuberculosis and its preparation method Download PDFInfo
- Publication number
- CN1785384A CN1785384A CN 200510045095 CN200510045095A CN1785384A CN 1785384 A CN1785384 A CN 1785384A CN 200510045095 CN200510045095 CN 200510045095 CN 200510045095 A CN200510045095 A CN 200510045095A CN 1785384 A CN1785384 A CN 1785384A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- medicine
- bletillae
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating pulmonary tuberculosis is prepared from 9 Chinese-medicinal materials includes astragalus root, pilose asiabell root, Chinese angelica root, red sage root, etc through pulverizing three of them including Chinese angelica root, etc and supercritical CO2 extracting to obtain volatile oil, inclusion by beta-cyclodextrin, supefine pulverizing of red sage root, and extracting of others in alcohol.
Description
(1) technical field under
The present invention relates to a kind of Chinese medicine composition for the treatment of pulmonary tuberculosis and preparation method thereof.
(2) background technology
At present, effectively treating phthisical medicine, mainly is Western medicine.But Western medicine generally has bigger toxic and side effects.The medicine of the treatment pulmonary tuberculosis that pure Chinese medicine is made, its curative effect is generally undesirable, can not effectively kill tuberculosis virus.
(3) summary of the invention
The present invention is in order to overcome the deficiency of above technology, a kind of good effect is provided, can have effectively killed the pure Chinese medicine composition of the treatment pulmonary tuberculosis of tuberculosis virus.
Another object of the present invention is to provide the preparation method of above-mentioned composition.
The Chinese medicine composition of treatment pulmonary tuberculosis of the present invention is to be made by following materials of weight proportions and pharmaceutic adjuvant: Radix Astragali 300-600g, Radix Codonopsis 200-500g, Rhizoma Polygonati 300-600g, Radix Angelicae Sinensis 200-500g, Radix Salviae Miltiorrhizae 200-500g, Radix Ranunculi Ternati 300-600g, Radix Stemonae 150-350g, Pseudobulbus Bletillae (Rhizoma Bletillae) 150-350g, Spica Prunellae 200-500g.
The Chinese medicine composition of the invention described above, the preferred weight proportion of described raw material is: Radix Astragali 350-500g, Radix Codonopsis 250-400g, Rhizoma Polygonati 350-500g, Radix Angelicae Sinensis 250-400g, Radix Salviae Miltiorrhizae 250-400g, Radix Ranunculi Ternati 350-500g, Radix Stemonae 200-300g, Pseudobulbus Bletillae (Rhizoma Bletillae) 200-300g, Spica Prunellae 250-400g.
The Chinese medicine composition of the invention described above, the most preferred weight proportion of described raw material are Radix Astragali 420g, Radix Codonopsis 336g, Rhizoma Polygonati 420g, Radix Angelicae Sinensis 336g, Radix Salviae Miltiorrhizae 336g, Radix Ranunculi Ternati 420g, Radix Stemonae 252g, Pseudobulbus Bletillae (Rhizoma Bletillae) 252g, Spica Prunellae 336g.
The Chinese medicine composition of the invention described above preferably is prepared into the chewable tablet tablet.
Chinese medicine composition of the present invention, clinical proved recipe for the Pneumology Department head of the department of internal medicine doctor of Hospital Attached to Shandong Chinese Medical Univ., the Tao Kai of Chinese Internal Medicine teaching and research room of Shandong Traditional Chinese Medicine University professor, belong to new Chinese medicine 6 classes, this problem has been listed in national 863 emphasis problems.The composition that raw material keeps after extracting is oligosaccharide and polysaccharide mostly, and mouthfeel is good, so we are chewable tablet with dosage form design, has promptly kept the effective ingredient of traditional water decoct, has made things convenient for the patient to take, and also is convenient to storage and transport, has enlarged sale colony.Can bring into play drug effect rapidly than conventional tablet, improve bioavailability.
Fang Xiewei: Radix Astragali QI invigorating, benefit essence are monarch drug; Radix Codonopsis, Rhizoma Polygonati supplementing QI and nourishing YIN are auxilliary minister; Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae are enriched blood, blood circulation promoting and blood stasis dispelling, also are auxilliary minister, the meaning of getting Radix Angelicae Sinensis decoction for tonifying blood, enrich and benefit essence and blood, but Radix Salviae Miltiorrhizae nourishing blood and promoting blood circulation then; Radix Ranunculi Ternati, the Radix Stemonae kill the consumptive disease worm, clearind deficient heat is assistant; Pseudobulbus Bletillae (Rhizoma Bletillae) convergence lung qi, eliminating blood stasis to promote regeneration of blood are assistant, and Spica Prunellae lung heat clearing deficiency-heat also is an adjuvant drug, helps the power of Radix Ranunculi Ternati clearind deficient heat again.Full side's compatibility, but benefiting essence-blood, tonifying the lung gas kills the consumptive disease worm, clearind deficient heat, promoting tissue regeneration by removing blood stasis, the effect of playing QI invigorating, yin nourishing, blood stasis dispelling parasite killing altogether.
Chinese medicine composition of the present invention is used for the treatment of III, IV type pulmonary tuberculosis progressive stage disease clinically at present, pulmonary tuberculosis active stage cooperation Western medicine chemotherapy attenuation synergistic reduces drug resistance, strengthens tuberculosis, and it is particularly outstanding to reduce lung tissue infringement aspect.Use at active stage associating Western medicine lungy, reduce drug resistance, increase local blood circulation, increase pulmonary's blood drug level, improve tuberculosis; At the tuberculosis stable phase, use anti-consumptive disease sheet to reduce the lung tissue damage separately, accelerate the pathological tissue reparation, consolidate curative effect, human body immunity improving power prevents that recurrence from having significant curative effect.
The Therapeutic Principle of pulmonary tuberculosis is that tonify deficiency is main, and ginseng is with parasite killing.Respectively distinguishing the flavor of among the we, water miscible polysaccharide is the main component of human body immunity improving power in the medicine, and fat-soluble composition has certain inhibitory action to the Bacillus tuberculosis.Consider the practical condition of factory, take into account fat-soluble and water soluble ingredient that with reference to the extraction process of Radix Astragali essenc oral liquid, we work out alcoholic acid aqueous solution percolation temporarily and extract each composition simultaneously.Percolation belongs to dynamic leaching, and promptly the relative medicated powder of solvent flows and leaches, the utilization rate height of solvent, and effective ingredient leaches fully, and guarantees that effective ingredient is not destroyed.
Contain volatile oil in Radix Angelicae Sinensis, Spica Prunellae and the Radix Ranunculi Ternati, volatile oil can be treated the cough that pulmonary tuberculosis causes in we, and the effect that diminishes inflammation is arranged, still, because some volatile ingredient, to heat, photo-labile, so we adopt CO
2The method of supercritical extraction volatile oil has not only made things convenient for the operation of big production, has also guaranteed the quality of extract.
The selection of adjuvant: add an amount of aspartame and make the mouthfeel of tablet better, add the viscosity that starch reduces dry extract.Do bonding agent with ethanol, 90% ethanol system soft material viscosity is too strong, and 95% ethanol system soft material is pinched promptly and loose, and is beneficial to granulation.Reduce the moisture absorption of material, the flowability that increases material is beneficial to tablet weight variation.Comprehensively relatively determine to select for use magnesium stearate, it both can give the material good mobility, again the energy protection against the tide because of its hydrophobicity.
The preparation method of the Chinese medicine composition of the invention described above preferably adopts following steps to carry out,
(1), Radix Angelicae Sinensis, Spica Prunellae and Radix Ranunculi Ternati are pulverized, use CO
2The supercritical extraction device extracts volatile oil; Beta-schardinger dextrin-is dissolved in the suitable quantity of water, after the grinding, adds the volatile oil after extracting, grind, sucking filtration, petroleum ether gets inclusion complex behind the freeze-day with constant temperature;
(2), the medicinal residues after the supercritical extraction are mixed with the Radix Astragali, Radix Codonopsis, Rhizoma Polygonati, the Radix Stemonae and the Pseudobulbus Bletillae (Rhizoma Bletillae) of pulverizing, the alcoholic solution percolation that adds 10 times of weight 50% extracts, it is the clear paste of 1.20-1.26 to density that extracting solution reclaims ethanol, then, clear paste is continued to be concentrated into the thick extractum that density is 1.34-1.36, and drying under reduced pressure gets extract;
(3) Radix Salviae Miltiorrhizae micronizing gets micropowders;
(4) with above-mentioned inclusion complex, extract, micropowders and pharmaceutic adjuvant, cross 100 mesh sieve mixings, tabletting is made chewable tablet.
One, gets medicine of the present invention and carry out following Tuberculosis in vitro nuclear tests (providing data) by Beijing Tuberculosis and Thoracic Tumor Research Institute medicine chamber of grinding
1. culture medium: 7H9 fluid medium (containing 10%ADC), 7H10 solid medium (containing 10%OADC, 0.03% agar).
2. medicine and processing thereof (test tube doubling dilution): the mixture of the inclusion complex among the medicine embodiment 1 of the present invention, extract, micropowders.Isoniazid (INH) is a Sigma company product.Medicine of the present invention and INH make solution (storing solution) just with dissolved in distilled water respectively, after the sterilization, make it be designed concentration in culture medium.
Experimental bacteria and in culture medium concentration: experimental bacteria is mycobacterium tuberculosis type strain H
37Rv.Will be on modified Russell medium well-grown culture, wear into bacteria suspension with agate mortar, make it become following concentration in culture medium: (1) is 10 in the 7H9 fluid medium
-2Mg/ml; (2) on the 7H10 culture medium slant, inoculate 10
-3The bacteria suspension 0.1ml of mg/ml.
4. cultivate with observation and put 37 ℃ of cultivations, be as the criterion with the result around cultivating.
5. result
5.1 the minimal inhibitory concentration (MIC) of institute's reagent thing is as table 1 in the 7H9 fluid medium.
The MIC of table 1 in the 7H9 fluid medium
| Medicine | MIC |
| Medicine INH of the present invention | 5.0(mg/ml) 0.025(μg/ml) |
5.2 the MIC such as the table 2 of institute's reagent thing in the 7H10 solid medium.
The MIC of table 2 in the 7H10 culture medium
| Medicine | MIC |
| Medicine INH of the present invention | 1.56(mg/ml) 0.125(μg/ml) |
Under this experiment condition, medicine of the present invention is in the 7H9 fluid medium, to H
37The MIC of Rv is 5.0mg/ml, in the 7H10 solid medium, to H
37The MIC of Rv is 1.56mg/ml.
Two, (following pharmacodynamic experiment and toxicity test are all undertaken by Xiyuan Hospital, Chinese Medicine Academy of China the antibacterial action of medicine of the present invention, test commencement date and deadline: in July, 2005～2005 year November)
1. strain: the clinical isolating pathogenic strain of this test, comprise each 1 strain of staphylococcus aureus 9 strains, staphylococcus epidermidis 10 strains, micrococcus catarrhalis 3 strains, streptococcus 10 strains, bacillus pyocyaneus 4 strains, Bacillus proteus 6 strains, Escherichia coli 9 strains, pneumobacillus 6 strains and staphylococcus aureus, bacillus pyocyaneus and escherichia coli Quality Control strain, totally 60 strains provide by Inst. of Medicinal Biological Technology, Chinese Academy of Medical Sciences.
2. medicine: extract drugs clear paste of the present invention: 1.9474g crude drug/g clear paste, provide lot number by Shandong Runhua Pharmaceutical Co., Ltd.: be made into the medicinal liquid of 1g crude drug/ml concentration with distilled water, 100 ℃ of sterilizations in 30 minutes, cool back 2000 rev/mins 10 minutes centrifugal, getting supernatant, to put refrigerator standby.
3. test method: with crude drug concentration is that the extract drugs clear paste of the present invention of 1g/ml is diluted to the medicinal liquid that contains crude drug 100,50,25,12.5,6.25,3.125,1.56mg/ml concentration with the M-H culture medium, the medicinal liquid 100 μ l/ holes of each concentration are added respectively in the 96 aseptic well culture plates successively, totally 65 be listed as, every plate is established the medicine contrast that 1 row do not add antibacterial.
The fresh bacterial cultures of dilution in 1: 1000 is joined in the good pastille culture plate of above-mentioned each row's dilution, 10 μ l/ holes, other establishes each bacterial strain control wells of not dosing.Streptococcus is put 5%CO
2, cultivated 20 hours in 37 ℃ of calorstats, other each bacterium is put and cultivates observed result after 20～48 hours in 37 ℃ of incubators.The minimum dilution drug level of no bacterial growth is minimal inhibitory concentration (MIC).In this test, MIC＞100mg/ml is decided to be no bacteriostasis, calculates total suppression ratio and MIC
50
4. result: medicine of the present invention has inhibitory action to coccuses such as staphylococcus aureus, staphylococcus epidermidis, micrococcus catarrhalises, and suppression ratio is respectively 90,70 and 100%, and bacillus such as bacillus pyocyaneus, escherichia coli, pneumobacillus do not have inhibitory action.Total suppression ratio of medicine of the present invention is 35%, MIC
50Be 12.32mg/ml.
Three, the refrigeration function of medicine of the present invention
1. trial drug: extract drugs clear paste of the present invention, 1.9474g crude drug/g clear paste is provided lot number by Shandong Runhua Pharmaceutical Co., Ltd.: the rat dosage is respectively 5.0,2.5,1.25g crude drug/kg.With distilled water be made into 0.5,0.25,0.125g crude drug/ml medicinal liquid is standby: similar contrast medicine BAIDI ZIYIN WAN, poplar Wenshui, Shanxi pharmaceutical Co. Ltd product, lot number: 20050453.Rat dosage 1.6g/kg.It is standby to be made into 0.16g crude drug/ml medicinal liquid with distilled water.The positive control drug Aspirin Enteric-coated Tablets, 40mg/ sheet, the limited company limited product of Beijing dawn Pharmaceutical, lot number: 040311.Dosage is 200mg/kg, and the medicinal liquid that is made into 20mg/ml concentration with distilled water is standby.
2. pyrogen: yeast tablet, every contains yeast 0.5g, Guangdong Wuzhou Pharmaceutical Co., Ltd.'s product, lot number: 051202.Being made into 15% bacteria suspension with normal saline uses.
3。Test method: laboratory animal is divided into 6 groups at random, that is: model control group (equivalent distilled water), aspirin group (200mg/kg), BAIDI ZIYIN WAN group (1.6g/kg), medicine low dose of the present invention (group of 1.25g crude drug/kg), middle dosage (2.5g crude drug/kg) group and heavy dose of (5.0g/kg) group, 10 every group.Measure three rat anus temperature for three days on end and average and make normal body temperature before the pyrogenicity, the abnormal rat of body temperature is rejected.Back part of animal subcutaneous injection yeast suspension (15% during test, 10ml/kg), the administration group is irritated the stomach medicine 1 time simultaneously, the model control group group gives the equivalent distilled water, administration 1 time again behind the 4h, behind medicine 3,4,5,6,7,8h measures rat temperature, the variation of calculating each time point body temperature, between organizing relatively.With the body temperature changing value is vertical coordinate, is the abscissa mapping with time.
4. result: 3h body temperature begins to raise gradually behind the model group rat injection yeast, and 7h peaks, and then body temperature descends gradually; 3～7h body temperature obviously descends behind the large, medium and small dosage group of the medicine of the present invention medicine, significantly is lower than model control group (P＜0.05～0.001).3～7h fervescence amplitude is starkly lower than model control group (P＜0.05～0.001) behind the aspirin group medicine; Also significantly decline (P＜0.05～0.01) of 3～7h body temperature behind the similar contrast medicine BAIDI ZIYIN WAN group medicine.Show that medicine of the present invention has tangible refrigeration function to yeast pyrogenicity rat temperature.
Four, medicine of the present invention is to the antitussive action of citric acid institute Cavia porcellus
1. medicine:
(1) be subjected to reagent extract drugs clear paste of the present invention: contain 1.9474g crude drug/g clear paste, lot number:.Shandong Runhua Pharmaceutical Co., Ltd. provides.Divide three dosage groups, dosage be 4.4 (greatly), 2.2 (in), 1.1 (little) g crude drug/kg.With distilled water be mixed with 0.44, and the medicinal liquid of 0.22g, 0.11g (crude drug)/ml to put refrigerator standby.
(2) positive control drug: cloperastine tablet, the 10mg/ sheet, produce lot number by Beijing dawn Pharmaceutical Co., Ltd: 030619, dosage is 7mg/kg, the medicinal liquid that is made into 0.7mg/ml with distilled water is standby.BAIDI ZIYIN WAN, the 18g/ ball, poplar Wenshui, Shanxi pharmaceutical Co. Ltd produces, authentication code: the accurate word B20020590 of traditional Chinese medicines, product batch number: 20050453, dosage is 1.4g/kg, the medicinal liquid that is made into 0.14g/ml with distilled water is standby.
2. test method
Preceding Cavia porcellus is pursued of test only places in the airtight bell jar of 4L container, pressure with (600mmHg) sprays into 17.5% citric acid by the glass shower nozzle, sprays 1 minute, and the cough number of times that writes down Cavia porcellus in 5 minutes screens, the cough number of times is less than 10 persons to be abandoned, and selects qualified Cavia porcellus and is used for test.
Get 60 of the qualified Cavia porcelluss in screening back, male and female half and half are divided into 6 groups at random, (1) model group (feedwater); (2) cloperastine tablet group (7mg/kg); (3) hundred ground YIN nourishing groups (1.4g/kg); (4) medicine of the present invention is heavy dose of organizes (the 4.4g crude drug/kg); (5) (the 2.2g crude drug/kg) of dosage group in the medicine of the present invention; (6) medicine small dose group of the present invention (1.1g crude drug/kg), with volume gastric infusion every day of 10ml/kg once, for three days on end, after the last administration 90 minutes, Cavia porcellus by only inserting in the volumetrical airtight bell jar of 4L, is sprayed into 17.5% citric acid with the pressure of (600mmHg) by the glass shower nozzle, sprayed 1 minute, the cough latent period of observed and recorded Cavia porcellus and the number of times of coughing in 5 minutes are through t check, comparable group differences.
3. the result shows, medicine of the present invention is big or middle, the dosage group obviously reduces the cough number of times, with model group significant difference is arranged relatively, (P＜0.05～0.01) respectively, large, medium and small dosage group all has the trend that prolongs cough latent period, contrast medicine BAIDI ZIYIN WAN can obviously prolong cough latent period and reduce the cough number of times, with model group significant difference (P＜0.01) is arranged relatively, and the cloperastine tablet effect is not obvious.
Five, long term toxicity test
Continuous 13 week of gastric infusion of medicine 27.25,13.88 of the present invention and 6.94g crude drug/kg (clinical consumption 70,35,17.5 times) treated animal, each treated animal was not seen serious adverse reaction, food ration, routine blood test, biochemical 12 indexs, electrocardiogram, internal organs index equal no difference of science of statistics between each group.Each internal organs of pathologic finding there is no the obvious toxic pathology change that this guiding drug rises.
Six, acute toxicity testing
With the dosage gastric infusion of 40ml/kg body weight once after, the mice statvolt is moving less, perpendicular hair is eaten less, drinks less, crosses approximately to recover normal substantially behind 2～3h; After the administration for the second time in 6 hours symptom same as described above appears at interval; The 3rd administration after 16 hours, symptom is identical.Stool, behavior, spirit etc. are basic after 24 hours recovers normal, and fur also recovers normally, with the relatively more equal indistinction of normal control group; The flow control basic recovery in 3～4 days of ingesting is normal.Food ration reduces after the administration in first day, and body weight obviously reduces, but food ration is recovered the normal while gradually, grows also well, and body weight is also recovered to such an extent that do not have difference (seeing table 1, table 2 for details) with normal group.The all no abnormal phenomenons of other system such as nerve, breathing are observed the 14th day no animal dead always, and anatomic observation is not seen macroscopic pathological changes.
Medicine of the present invention is used for the treatment of pulmonary tuberculosis and has good effect, can effectively kill tuberculosis virus, made by pure Chinese medicine.
Preparation method of the present invention has the dna purity height, the advantage that drug loss is few.
(4) specific embodiment
Embodiment 1:
Take by weighing the raw material for standby of following weight: Radix Astragali 420g, Radix Codonopsis 336g, Rhizoma Polygonati 420g, Radix Angelicae Sinensis 336g, Radix Salviae Miltiorrhizae 336g, Radix Ranunculi Ternati 420g, Radix Stemonae 252g, Pseudobulbus Bletillae (Rhizoma Bletillae) 252g, Spica Prunellae 336g.
1, the Chinese medicine (except that Radix Salviae Miltiorrhizae) of respectively distinguishing the flavor of in will writing out a prescription is pulverized standby;
2, with Radix Angelicae Sinensis, Spica Prunellae and Radix Ranunculi Ternati pulverizing CO
2The supercritical extraction instrument extracts volatile oil; Extraction temperature, pressure and time are respectively 45 ℃, 30MPa, 3h.
3, beta-schardinger dextrin-is dissolved in the water of 20 times of amounts, grinds 5min, add volatile oil (50% alcoholic solution (V/V)), grinding is 90 minutes, refrigerator (4 ℃) cold preservation 24h, and sucking filtration, petroleum ether, 40 ℃ of freeze-day with constant temperature 4h promptly get inclusion complex.
4, the medicinal residues of supercritical extraction and the Radix Astragali, Radix Codonopsis, Rhizoma Polygonati, the Radix Stemonae and the Pseudobulbus Bletillae (Rhizoma Bletillae) of pulverizing are extracted with 12 times of amounts, 50% alcoholic acid alcoholic solution percolation, flow velocity is (6ml/min/kg) 18ml/min, it is the clear paste of 1.20-1.26 to density that medicinal liquid reclaims ethanol, then, clear paste is continued to be concentrated into the thick extractum that density is 1.34-1.36, get extract;
5, drying under reduced pressure;
6, Radix Salviae Miltiorrhizae micronizing gets micropowders;
7, inclusion complex, extract, the micropowders of above steps gained are crossed 100 mesh sieve mixings, add 95% ethanol system soft material, 16 mesh sieve granulate are crossed in oven dry, add appropriate amount of starch, aspartame and 0.8% magnesium stearate mixing, tabletting;
8, with the plain coating tablets of gained, get 1000 of finished products;
9, packing;
10, warehouse-in.
Usage and consumption: this product is a chewable tablet, one time 3,3 times on the one.
Embodiment 2:
Take by weighing the raw material for standby of following weight: Radix Astragali 350g, Radix Codonopsis 400g, Rhizoma Polygonati 530g, Radix Angelicae Sinensis 250g, Radix Salviae Miltiorrhizae 220g, Radix Ranunculi Ternati 380g, Radix Stemonae 250g, Pseudobulbus Bletillae (Rhizoma Bletillae) 230g, Spica Prunellae 450g.
Preparation method, usage and consumption are substantially the same manner as Example 1, are prepared into chewable tablet.
Embodiment 3
Take by weighing the raw material for standby of following weight: Radix Astragali 500g, Radix Codonopsis 280g, Rhizoma Polygonati 360g, Radix Angelicae Sinensis 450g, Radix Salviae Miltiorrhizae 300g, Radix Ranunculi Ternati 500g, Radix Stemonae 200g, Pseudobulbus Bletillae (Rhizoma Bletillae) 200g, Spica Prunellae 250g.
1, the Chinese medicine (except that Radix Salviae Miltiorrhizae) of respectively distinguishing the flavor of in will writing out a prescription is pulverized standby;
2, Radix Angelicae Sinensis, Spica Prunellae and Radix Ranunculi Ternati are pulverized, adopt steam distillation to extract volatile oil; Beta-schardinger dextrin-is dissolved in the water of 20 times of amounts, grinds 5min, add volatile oil (50% alcoholic solution (V/V)), grinding is 90 minutes, sucking filtration, and petroleum ether, dry 4h promptly gets inclusion complex.
3, the Radix Astragali, Radix Codonopsis, Rhizoma Polygonati, the Radix Stemonae and the Pseudobulbus Bletillae (Rhizoma Bletillae) with medicinal residues after the water vapour extraction and pulverizing extracts twice with 10 times of amounts, 60% alcoholic acid alcoholic solution, and merge extractive liquid, filters, and being concentrated into density is the thick extractum of 1.34-1.36, and drying under reduced pressure gets extract;
4, Radix Salviae Miltiorrhizae micronizing gets micropowders;
7, inclusion complex, extract, the micropowders of above steps gained are crossed 100 mesh sieve mixings, add 95% ethanol system soft material, 16 mesh sieve granulate are crossed in oven dry, add an amount of lactose, dress up 1000 capsules, the 0.5g/ grain.
Usage and consumption: oral, one time 2,3 times on the one.
Embodiment 4
Take by weighing the raw material for standby of following weight: Radix Astragali 450g, Radix Codonopsis 300g, Rhizoma Polygonati 400g, Radix Angelicae Sinensis 250g, Radix Salviae Miltiorrhizae 380g, Radix Ranunculi Ternati 420g, Radix Stemonae 300g, Pseudobulbus Bletillae (Rhizoma Bletillae) 200g, Spica Prunellae 400g.
1, Radix Salviae Miltiorrhizae is pulverized, got the Radix Salviae Miltiorrhizae fine powder;
2, all the other raw materials are mixed, be ground into coarse powder, adds 10 times of amounts, 50% alcoholic acid alcoholic solution and extract twice, merge extractive liquid, filters, and is concentrated into density and is 1.3 thick extractum, and drying under reduced pressure gets extract;
3, the extract and the Radix Salviae Miltiorrhizae fine powder of above steps gained are crossed 100 mesh sieve mixings, add 95% ethanol system soft material, 16 mesh sieve granulate are crossed in oven dry, add an amount of dextrin, are prepared into granule 1000 bags, 8g/ grain with conventional method.
Usage and consumption: oral, one time 1 bag, 2 times on the one.
Claims (5)
1. Chinese medicine composition for the treatment of pulmonary tuberculosis, it is characterized in that: be to make by following materials of weight proportions and pharmaceutic adjuvant, Radix Astragali 300-600g, Radix Codonopsis 200-500g, Rhizoma Polygonati 300-600g, Radix Angelicae Sinensis 200-500g, Radix Salviae Miltiorrhizae 200-500g, Radix Ranunculi Ternati 300-600g, Radix Stemonae 150-350g, Pseudobulbus Bletillae (Rhizoma Bletillae) 150-350g, Spica Prunellae 200-500g.
2. Chinese medicine composition according to claim 1, it is characterized in that: the weight proportion of described raw material is Radix Astragali 350-500g, Radix Codonopsis 250-400g, Rhizoma Polygonati 350-500g, Radix Angelicae Sinensis 250-400g, Radix Salviae Miltiorrhizae 250-400g, Radix Ranunculi Ternati 350-500g, Radix Stemonae 200-300g, Pseudobulbus Bletillae (Rhizoma Bletillae) 200-300g, Spica Prunellae 250-400g.
3. Chinese medicine composition according to claim 1 is characterized in that: the weight proportion of described raw material is Radix Astragali 420g, Radix Codonopsis 336g, Rhizoma Polygonati 420g, Radix Angelicae Sinensis 336g, Radix Salviae Miltiorrhizae 336g, Radix Ranunculi Ternati 420g, Radix Stemonae 252g, Pseudobulbus Bletillae (Rhizoma Bletillae) 252g, Spica Prunellae 336g.
4. Chinese medicine composition according to claim 1 is characterized in that: be prepared into the chewable tablet tablet.
5. the preparation method of the described Chinese medicine composition of claim 4 is characterized in that: may further comprise the steps,
(1), Radix Angelicae Sinensis, Spica Prunellae and Radix Ranunculi Ternati are pulverized, use CO
2The supercritical extraction device extracts volatile oil; Beta-schardinger dextrin-is dissolved in the suitable quantity of water, after the grinding, adds the volatile oil after extracting, grind, sucking filtration, petroleum ether gets inclusion complex behind the freeze-day with constant temperature;
(2), the medicinal residues after the supercritical extraction are mixed with the Radix Astragali, Radix Codonopsis, Rhizoma Polygonati, the Radix Stemonae and the Pseudobulbus Bletillae (Rhizoma Bletillae) of pulverizing, the alcoholic solution percolation that adds 10 times of weight 50% extracts, it is the clear paste of 1.20-1.26 to density that extracting solution reclaims ethanol, then, clear paste is continued to be concentrated into the thick extractum that density is 1.34-1.36, and drying under reduced pressure gets extract;
(3) Radix Salviae Miltiorrhizae micronizing gets micropowders;
(4) with above-mentioned inclusion complex, extract, micropowders and pharmaceutic adjuvant, cross 100 mesh sieve mixings, tabletting is made chewable tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510045095XA CN100376283C (en) | 2005-11-17 | 2005-11-17 | Chinese medicinal composition for treating tuberculosis and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510045095XA CN100376283C (en) | 2005-11-17 | 2005-11-17 | Chinese medicinal composition for treating tuberculosis and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1785384A true CN1785384A (en) | 2006-06-14 |
| CN100376283C CN100376283C (en) | 2008-03-26 |
Family
ID=36783052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200510045095XA Expired - Fee Related CN100376283C (en) | 2005-11-17 | 2005-11-17 | Chinese medicinal composition for treating tuberculosis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100376283C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101812067A (en) * | 2010-04-08 | 2010-08-25 | 苏州宝泽堂医药科技有限公司 | Method for extracting stemonine from tuber stemona root |
| CN101461913B (en) * | 2008-11-27 | 2011-09-21 | 浙江省中西医结合医院 | Chinese medicinal composition for treating tuberculosis |
| CN101537150B (en) * | 2009-04-29 | 2013-07-24 | 北京星昊医药股份有限公司 | Medicine for treating pulmonary tuberculosis |
| CN103773588A (en) * | 2012-10-25 | 2014-05-07 | 奇复康药物研发(苏州)有限公司 | Extraction technology for ranunculus ternatus thunb essential oil |
| CN104435103A (en) * | 2014-12-09 | 2015-03-25 | 刘庆斌 | Traditional Chinese medicine composition for treating pulmonary tuberculosis and acupoint combined acupuncture application |
| CN107837358A (en) * | 2017-11-16 | 2018-03-27 | 钟千里 | One kind treats phthisical Chinese medicine preparation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1136861C (en) * | 2000-04-07 | 2004-02-04 | 卢庆来 | 'Lifeiqing' capsule for treating pulmonary tuberculosis |
-
2005
- 2005-11-17 CN CNB200510045095XA patent/CN100376283C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101461913B (en) * | 2008-11-27 | 2011-09-21 | 浙江省中西医结合医院 | Chinese medicinal composition for treating tuberculosis |
| CN101537150B (en) * | 2009-04-29 | 2013-07-24 | 北京星昊医药股份有限公司 | Medicine for treating pulmonary tuberculosis |
| CN101812067A (en) * | 2010-04-08 | 2010-08-25 | 苏州宝泽堂医药科技有限公司 | Method for extracting stemonine from tuber stemona root |
| CN103773588A (en) * | 2012-10-25 | 2014-05-07 | 奇复康药物研发(苏州)有限公司 | Extraction technology for ranunculus ternatus thunb essential oil |
| CN104435103A (en) * | 2014-12-09 | 2015-03-25 | 刘庆斌 | Traditional Chinese medicine composition for treating pulmonary tuberculosis and acupoint combined acupuncture application |
| CN107837358A (en) * | 2017-11-16 | 2018-03-27 | 钟千里 | One kind treats phthisical Chinese medicine preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100376283C (en) | 2008-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100376283C (en) | Chinese medicinal composition for treating tuberculosis and its preparation method | |
| CN1850153A (en) | Method for preparing Radix puerariae and cenlian decoction | |
| CN1730015A (en) | Honey suckle extract and its preparing process and application | |
| CN101850032A (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN102068464B (en) | Antibacterial and antiviral effective part extract of medicated leaven and medicinal use thereof | |
| CN1957972A (en) | Composition in use for invigorating primordial energy, benefiting pubic region, preparation method and usage | |
| CN1943734A (en) | A Chinese traditional medicine for clearing away heat and toxic material | |
| CN1094762C (en) | Fresh rehmannia root extract for proliferation of bifidobactor and extraction method thereof | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN106511401A (en) | Preparation method and application of cordyceps taii mycelia polysaccharides | |
| CN1267120C (en) | Frozen dry powder injection of houttuynia cordata and its preparation | |
| CN101032524A (en) | Application of martianus dermestoides in producing oxygen-deficient resisting medicine or healthy food and the preparing method | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application | |
| CN111729056A (en) | Anticancer medicine composition and its prepn | |
| CN1432391A (en) | Recipe of Chinese medicine with treating and health care functions | |
| CN103417653A (en) | Veterinary-use compound pure Chinese herbal medicine for treating coccidium and preparation method of oral liquid of same | |
| CN107296827B (en) | anti-H1N 1 influenza A pharmaceutical composition and application thereof | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN102266519A (en) | Chinese medicinal composition for treating tuberculosis and preparation method thereof | |
| CN113966837A (en) | Health food with anxiolytic and antidepressant functions | |
| CN1895574A (en) | Chinese-medicinal preparation for treating urinary system disease | |
| CN1840081A (en) | Diabetes-treating tablet and preparation method thereof | |
| CN1724007A (en) | Medicine contg. zinc, honeysuckle, Radix scutellariae and forsynthia fruit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080326 Termination date: 20181117 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |